Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL DRUG DEVICE COMBINATION MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL DRUG DEVICE COMBINATION MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL DRUG DEVICE COMBINATION MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S 5 FORCES
5.3 PATENT ANALYSIS
5.4 GLOBAL DRUG DEVICE COMBINATION MARKET ANALYSIS
6 EPIDEMOLOGY
6.1 EPIDEMOLOGY OF CANCER
6.2 EPIDEMOLOGY OF DIABETES DISORDERS
6.3 EPIDEMOLOGY OF CARDIOVASCULAR DISORDERS
6.4 EPIDEMOLOGY OF RESPIRATORY DISORDERS
7 INDUSTRY INSIGHTS
7.1 DEMOGRAPHIC TRENDS
7.2 KEY PRICING STRATEGIES
7.3 KEY PATIENT ENROLLMENT STRATEGIES
7.4 INTERVIEWS WITH MANUFACTURING COMPANIES
7.5 OTHER KOL SNAPSHOTS
8 REGULATORY FRAMWORK
9 GLOBAL DRUG DEVICE COMBINATION MARKET, BY PRODUCT
9.1 OVERVIEW
9.2 TRANSDERMAL PATCHES
9.2.1 BY TYPE
9.2.1.1. RESERVOIR
9.2.1.2. MATRIX
9.2.1.3. OTHERS
9.2.2 BY TECHNOLOGY
9.2.2.1. ELECTRIC CURRENT
9.2.2.2. MECHANICAL ARRAYS
9.2.2.3. THERMAL ABLATION
9.2.2.4. CHEMICAL ENHANCERS
9.2.2.5. OTHERS
9.3 INHALERS
9.3.1 DRY POWDER
9.3.2 NEBULIZERS
9.3.2.1. ULTRASONIC
9.3.2.2. COMPRESSOR
9.3.2.3. MESH
9.3.3 METERED DOSE
9.3.3.1. BY TYPE
9.3.3.1.1. MANNUALY ACTIVATED PRESSSURIZED
9.3.3.1.2. BREATH ACTUATED PRESSURIZED INHALERS
9.4 INFUSION PUMPS
9.4.1 VOLUMETRIC
9.4.2 DISPOSABLES
9.4.3 SYRINGES
9.4.3.1. SINGLE CHAMBER PREFILLED SYRINGE
9.4.3.2. DUAL CHAMBER PREFILLED SYRINGE
9.4.3.3. CUSTOMIZED PREFILLED SYRINGE
9.4.3.4. OTHERS
9.4.4 AMBULATORY
9.4.5 IMPLANTABLES
9.4.5.1. BIODEGRADABLE IMPLANTS
9.4.5.1.1. POLYESTERAMIDE
9.4.5.1.2. POLY LACTIC-CO-GLYCOLIC ACID
9.4.5.2. NO BIODEGRADABLE IMPLANTS
9.4.5.2.1. ETHYLENE-VINYL ACETATE
9.4.5.2.2. SILICONE
9.4.5.2.3. THERMOPLASTIC POLYURETHANE
9.4.6 INSULIN
9.4.6.1. LONG ACTING
9.4.6.2. REGULAR/SHORT ACTING
9.4.6.3. INTERMEDIATE ACTING
9.4.6.4. RAPID ACTING
9.4.6.5. PREMIX
9.4.7 OTHERS
9.5 DRUG ELUTING STENTS
9.5.1 BY COATING
9.5.1.1. POLYMER BASED COATING
9.5.1.2. POLYMER FREE COATING
9.5.2 BY USAGE
9.5.2.1. CORONARY STENTS
9.5.2.2. PERIPHERALVASCULAR STENTS
9.5.3 BY GENERATION
9.5.3.1. 1ST GENERATION
9.5.3.2. 2ND GENERATION
9.5.3.3. 3RD GENERATION
9.5.3.4. 4 TH GENERATION
9.5.4 BY PLATFORM
9.5.4.1. STAINLESS STEEL
9.5.4.2. COBALT CHROMIUM
9.5.4.3. PLATANIUM CHROMIUM
9.5.4.4. NITINOL
9.5.4.5. OTHERS
9.6 ANTIMICROBIAL CATHETERS
9.6.1 UROLOGICAL
9.6.2 CARDIOVASCULAR
9.6.3 OTHERS
9.7 DIGITAL PILL
9.7.1 TABLET
9.7.2 CAPSULES
9.7.3 MICROCHIP
9.7.4 DELIVERY DEVICE
9.8 WOUND CARE COMBINATION PRODUCTS
9.9 DRUG DELIVERY HYDROGELS
9.9.1 BY SOURCE
9.9.1.1. NATURAL
9.9.1.2. SYNTHETHIC
9.9.1.3. HYBRID
9.9.2 BY DELIVERY ROUTE
9.9.2.1. OCULAR
9.9.2.2. SUBCUTANEOUS
9.9.2.3. ORAL CAVITY
9.9.2.4. TOPICAL
9.9.2.5. OTHERS
9.1 PHOTODYNAMIC THERAPY DEVICES
9.10.1 BY USAGE
9.10.1.1. CANCER
9.10.1.2. ACTINIC KERATOSIS
9.10.1.3. PSORIASIS
9.10.1.4. ACNE
9.10.1.5. OTHERS
9.11 ORTHOPEDIC COMBINATION PRODUCTS
9.11.1 BONE GRAFT IMPLANTS
9.11.2 ANTIBIOTIC BONE CEMENT
9.11.2.1. GENTAMICIN
9.11.2.2. GENTAMICIN PLUS VANCOMYCIN
9.11.2.3. GENTAMICIN PLUS CLINDAMYCIN
9.12 OTHERS
10 GLOBAL DRUG DEVICE COMBINATION MARKET, BY APPLICATION
10.1 OVERVIEW
10.2 CARDIOVASCULAR DISEASES
10.3 DIABETES
10.4 RESPIRATORY DISEASES
10.5 ORTHOPEDIC DISEASES
10.6 PAIN MANAGEMENT
10.7 DERMATOLOGY
10.8 CANCER
10.9 OTHERS
11 GLOBAL DRUG DEVICE COMBINATION MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.3 CLINICS
11.4 AMBULATORY SURGERY CENTERS
11.5 HOME CARE SETTINGS
11.6 OTHERS
12 GLOBAL DRUG DEVICE COMBINATION MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT TENDER
12.3 RETAIL SALES
12.3.1 HOSPITAL PHARMACY
12.3.2 ONLINE PHARMACY
12.3.3 RETAIL PHARMACY
13 GLOBAL DRUG DEVICE COMBINATION MARKET, BY REGION
13.1 GLOBAL DRUG DEVICE COMBINATION MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
13.2 NORTH AMERICA
13.2.1 U.S.
13.2.2 CANADA
13.2.3 MEXICO
13.3 EUROPE
13.3.1 GERMANY
13.3.2 FRANCE
13.3.3 U.K.
13.3.4 ITALY
13.3.5 SPAIN
13.3.6 RUSSIA
13.3.7 TURKEY
13.3.8 BELGIUM
13.3.9 NETHERLANDS
13.3.10 SWITZERLAND
13.3.11 REST OF EUROPE
13.4 ASIA-PACIFIC
13.4.1 JAPAN
13.4.2 CHINA
13.4.3 SOUTH KOREA
13.4.4 INDIA
13.4.5 AUSTRALIA
13.4.6 SINGAPORE
13.4.7 THAILAND
13.4.8 MALAYSIA
13.4.9 INDONESIA
13.4.10 PHILIPPINES
13.4.11 REST OF ASIA-PACIFIC
13.5 SOUTH AMERICA
13.5.1 BRAZIL
13.5.2 ARGENTINA
13.5.3 REST OF SOUTH AMERICA
13.6 MIDDLE EAST AND AFRICA
13.6.1 SOUTH AFRICA
13.6.2 SAUDI ARABIA
13.6.3 UAE
13.6.4 EGYPT
13.6.5 ISRAEL
13.6.6 REST OF MIDDLE EAST AND AFRICA
13.7 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
14 GLOBAL DRUG DEVICE COMBINATION MARKET, COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: GLOBAL
14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
14.3 COMPANY SHARE ANALYSIS: EUROPE
14.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
14.5 MERGERS & ACQUISITIONS
14.6 NEW PRODUCT DEVELOPMENT & APPROVALS
14.7 EXPANSIONS
14.8 REGULATORY CHANGES
14.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
15 GLOBAL DRUG DEVICE COMBINATION MARKET, COMPANY PROFILE
15.1 JANSSEN PHARMACEUTICA NV
15.1.1 COMPANY OVERVIEW
15.1.2 REVENUE ANALYSIS
15.1.3 GEOGRAPHIC PRESENCE
15.1.4 PRODUCT PORTFOLIO
15.1.5 RECENT DEVELOPEMENTS
15.2 AMGEN INC.
15.2.1 COMPANY OVERVIEW
15.2.2 REVENUE ANALYSIS
15.2.3 GEOGRAPHIC PRESENCE
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPEMENTS
15.3 GSK PLC
15.3.1 COMPANY OVERVIEW
15.3.2 REVENUE ANALYSIS
15.3.3 GEOGRAPHIC PRESENCE
15.3.4 PRODUCT PORTFOLIO
15.3.5 RECENT DEVELOPEMENTS
15.4 BD
15.4.1 COMPANY OVERVIEW
15.4.2 REVENUE ANALYSIS
15.4.3 GEOGRAPHIC PRESENCE
15.4.4 PRODUCT PORTFOLIO
15.4.5 RECENT DEVELOPEMENTS
15.5 MEDTRONIC
15.5.1 COMPANY OVERVIEW
15.5.2 REVENUE ANALYSIS
15.5.3 GEOGRAPHIC PRESENCE
15.5.4 PRODUCT PORTFOLIO
15.5.5 RECENT DEVELOPEMENTS
15.6 BAYER AG
15.6.1 COMPANY OVERVIEW
15.6.2 REVENUE ANALYSIS
15.6.3 GEOGRAPHIC PRESENCE
15.6.4 PRODUCT PORTFOLIO
15.6.5 RECENT DEVELOPEMENTS
15.7 THE LUBRIZOL CORPORATION
15.7.1 COMPANY OVERVIEW
15.7.2 REVENUE ANALYSIS
15.7.3 GEOGRAPHIC PRESENCE
15.7.4 PRODUCT PORTFOLIO
15.7.5 RECENT DEVELOPEMENTS
15.8 COSMED PHARMACEUTICAL CO.LTD.
15.8.1 COMPANY OVERVIEW
15.8.2 REVENUE ANALYSIS
15.8.3 GEOGRAPHIC PRESENCE
15.8.4 PRODUCT PORTFOLIO
15.8.5 RECENT DEVELOPEMENTS
15.9 CGBIO
15.9.1 COMPANY OVERVIEW
15.9.2 REVENUE ANALYSIS
15.9.3 GEOGRAPHIC PRESENCE
15.9.4 PRODUCT PORTFOLIO
15.9.5 RECENT DEVELOPEMENTS
15.1 E3D ELCAM DRUG DELIVERY DEVICES
15.10.1 COMPANY OVERVIEW
15.10.2 REVENUE ANALYSIS
15.10.3 GEOGRAPHIC PRESENCE
15.10.4 PRODUCT PORTFOLIO
15.10.5 RECENT DEVELOPEMENTS
15.11 EITAN MEDICAL LTD.
15.11.1 COMPANY OVERVIEW
15.11.2 REVENUE ANALYSIS
15.11.3 GEOGRAPHIC PRESENCE
15.11.4 PRODUCT PORTFOLIO
15.11.5 RECENT DEVELOPEMENTS
15.12 EOFLOW CO., LTD.
15.12.1 COMPANY OVERVIEW
15.12.2 REVENUE ANALYSIS
15.12.3 GEOGRAPHIC PRESENCE
15.12.4 PRODUCT PORTFOLIO
15.12.5 RECENT DEVELOPEMENTS
15.13 FINDAIR SP. Z O. O.
15.13.1 COMPANY OVERVIEW
15.13.2 REVENUE ANALYSIS
15.13.3 GEOGRAPHIC PRESENCE
15.13.4 PRODUCT PORTFOLIO
15.13.5 RECENT DEVELOPEMENTS
15.14 INSULET CORPORATION.
15.14.1 COMPANY OVERVIEW
15.14.2 REVENUE ANALYSIS
15.14.3 GEOGRAPHIC PRESENCE
15.14.4 PRODUCT PORTFOLIO
15.14.5 RECENT DEVELOPEMENTS
15.15 MEDIPRINT
15.15.1 COMPANY OVERVIEW
15.15.2 REVENUE ANALYSIS
15.15.3 GEOGRAPHIC PRESENCE
15.15.4 PRODUCT PORTFOLIO
15.15.5 RECENT DEVELOPEMENTS
15.16 METP® PHARMA AG
15.16.1 COMPANY OVERVIEW
15.16.2 REVENUE ANALYSIS
15.16.3 GEOGRAPHIC PRESENCE
15.16.4 PRODUCT PORTFOLIO
15.16.5 RECENT DEVELOPEMENTS
15.17 MICRON BIOMEDICAL, INC.
15.17.1 COMPANY OVERVIEW
15.17.2 REVENUE ANALYSIS
15.17.3 GEOGRAPHIC PRESENCE
15.17.4 PRODUCT PORTFOLIO
15.17.5 RECENT DEVELOPEMENTS
15.18 MICRONJET
15.18.1 COMPANY OVERVIEW
15.18.2 REVENUE ANALYSIS
15.18.3 GEOGRAPHIC PRESENCE
15.18.4 PRODUCT PORTFOLIO
15.18.5 RECENT DEVELOPEMENTS
15.19 OCUMEDIC, INC.
15.19.1 COMPANY OVERVIEW
15.19.2 REVENUE ANALYSIS
15.19.3 GEOGRAPHIC PRESENCE
15.19.4 PRODUCT PORTFOLIO
15.19.5 RECENT DEVELOPEMENTS
15.2 OTSUKA AMERICA PHARMACEUTICAL, INC
15.20.1 COMPANY OVERVIEW
15.20.2 REVENUE ANALYSIS
15.20.3 GEOGRAPHIC PRESENCE
15.20.4 PRODUCT PORTFOLIO
15.20.5 RECENT DEVELOPEMENTS
15.21 PROPELLER HEALTH
15.21.1 COMPANY OVERVIEW
15.21.2 REVENUE ANALYSIS
15.21.3 GEOGRAPHIC PRESENCE
15.21.4 PRODUCT PORTFOLIO
15.21.5 RECENT DEVELOPEMENTS
15.22 RAPHAS CO., LTD.
15.22.1 COMPANY OVERVIEW
15.22.2 REVENUE ANALYSIS
15.22.3 GEOGRAPHIC PRESENCE
15.22.4 PRODUCT PORTFOLIO
15.22.5 RECENT DEVELOPEMENTS
15.23 SENSIRION AG
15.23.1 COMPANY OVERVIEW
15.23.2 REVENUE ANALYSIS
15.23.3 GEOGRAPHIC PRESENCE
15.23.4 PRODUCT PORTFOLIO
15.23.5 RECENT DEVELOPEMENTS
15.24 SONCEBOZ
15.24.1 COMPANY OVERVIEW
15.24.2 REVENUE ANALYSIS
15.24.3 GEOGRAPHIC PRESENCE
15.24.4 PRODUCT PORTFOLIO
15.24.5 RECENT DEVELOPEMENTS
15.25 SUBCUJECT APS
15.25.1 COMPANY OVERVIEW
15.25.2 REVENUE ANALYSIS
15.25.3 GEOGRAPHIC PRESENCE
15.25.4 PRODUCT PORTFOLIO
15.25.5 RECENT DEVELOPEMENTS
15.26 VAXESS TECHNOLOGIES INC
15.26.1 COMPANY OVERVIEW
15.26.2 REVENUE ANALYSIS
15.26.3 GEOGRAPHIC PRESENCE
15.26.4 PRODUCT PORTFOLIO
15.26.5 RECENT DEVELOPEMENTS
15.27 VAXXAS
15.27.1 COMPANY OVERVIEW
15.27.2 REVENUE ANALYSIS
15.27.3 GEOGRAPHIC PRESENCE
15.27.4 PRODUCT PORTFOLIO
15.27.5 RECENT DEVELOPEMENTS
15.28 YPSOMED AG
15.28.1 COMPANY OVERVIEW
15.28.2 REVENUE ANALYSIS
15.28.3 GEOGRAPHIC PRESENCE
15.28.4 PRODUCT PORTFOLIO
15.28.5 RECENT DEVELOPEMENTS
15.29 TERUMO CORPORATION
15.29.1 COMPANY OVERVIEW
15.29.2 REVENUE ANALYSIS
15.29.3 GEOGRAPHIC PRESENCE
15.29.4 PRODUCT PORTFOLIO
15.29.5 RECENT DEVELOPEMENTS
15.3 TELEFLEX INCORPORATED
15.30.1 COMPANY OVERVIEW
15.30.2 REVENUE ANALYSIS
15.30.3 GEOGRAPHIC PRESENCE
15.30.4 PRODUCT PORTFOLIO
15.30.5 REVENUE ANALYSIS
16 CONCLUSION
17 QUESTIONNAIRE
18 ABOUT DATA BRIDGE MARKET RESEARCH
